Burlington, MA–based Lifordi Immunotherapeutics has secured a strategic investment from Sanofi Ventures, along with additional funding from existing backers ARCH Ventures, 5AM Ventures and Atlas Venture, bringing the company’s total capital raised to $112 million. The investment comes as the clinical-stage biotech prepares to report its first human data for LFD-200, a VISTA-targeted antibody-drug conjugate…